Elismetrep for treating migraine attacks
Part of Brain & nervous system clinical trials.
This study tests an investigational medicine called elismetrep (K-304) for treating migraine attacks quickly. If you have migraines, you take the medicine when a migraine starts and report how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had migraines (with or without aura) for at least one year.
- You have 2 to 10 moderate or severe migraine attacks per month (on average over the last 2 months).
- You can reliably tell your migraines apart from tension headaches.
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use birth control during the study (or abstain from sex).
- You have a personal smartphone (iPhone or Android) to use the study's diary app.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new inhaled powder form of a migraine medication called dihydroergotamine (DHE) to see if it safely and effectively stops migraine attacks. If you have frequent migraines, this trial might offer you a new treatment option to try.
This trial tests a new oral medication called elismetrep (K-304) for quickly stopping migraine pain and other symptoms. If you have regular migraines, this could offer a new option that works fast when a migraine starts.
This study tests an add-on migraine medicine (eptinezumab) given in the emergency room to quickly relieve a migraine attack, in addition to the usual care. It aims to see if this approach reduces pain and prevents the migraine from coming back.
This study looks at blood samples from people with migraine to find proteins and other markers that might explain why migraines happen. The goal is to better understand migraine, which could help find better treatments in the future.
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
This trial tests a new medicine, MEDI0618, against a placebo for people with episodic migraine. The goal is to see if MEDI0618 is safe and effective at reducing migraine days.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.